Exhibit 99.1

                    Study Finds that Removing Large
 Thrombus Before Treatment with Drug-Eluting Stents Improves Outcomes
                       in Heart Attack Patients

   Newly Published Results in the Journal of the American College of
   Cardiology Have Positive Implications for the Possis AngioJet(R)
                                System


   MINNEAPOLIS--(BUSINESS WIRE)--Aug. 9, 2007--Possis Medical, Inc.
(NASDAQ:POSS), a developer, manufacturer and marketer of pioneering
medical devices used in endovascular procedures, today announced the
formal publication of an important clinical study showing favorable
results for AngioJet(R) thrombectomy treatment of heart attack
patients with large thrombus (blood clot). The study shows that when
AngioJet thrombectomy is used to remove large thrombus before
placement of a drug-eluting stent (DES), it is associated with
significantly lower rates of subsequent death, repeat heart attack and
stent thrombosis. The work is authored by Dr. George Sianos and
colleagues at the ThoraxCenter in Rotterdam, the Netherlands, and
appears in the Journal of the American College of Cardiology (JACC),
volume 50, number 7, dated August 14, 2007. The publication can be
viewed on-line at http://content.onlinejacc.org.

   Dr. Sianos analyzed 812 consecutive heart attack patients
receiving a DES. Twenty-eight percent of the patients had large
thrombus that complicated their treatment. These patients had a much
higher incidence of serious adverse events out to two years after
treatment, compared to the other patients who did not have large
thrombus. The important exceptions were patients whose initial large
thrombus was removed with AngioJet thrombectomy before stenting: these
patients had a low incidence of serious adverse outcomes, similar to
those patients with little or no thrombus to begin with. AngioJet
thrombectomy was the single most powerful statistical predictor of a
good clinical outcome in such patients.

   Said Robert G. Dutcher, CEO of Possis Medical, Inc., "This
important study demonstrates that unresolved large thrombus is common
in acute coronary cases, and that placing a DES without first removing
the thrombus contributes significantly to later life-threatening
complications, including stent thrombosis. AngioJet thrombectomy
lowers this risk by safely converting a clotted vessel that is at high
risk for worse clinical outcomes into an un-clotted, low-risk vessel
that can be successfully stented. We believe these results offer an
important perspective that addresses some of the current uncertainty
regarding DES use in higher-risk settings."

   According to Dutcher, Dr. Sianos presented these key results at
several important medical meetings in the last year, including the
October 2006 Transcatheter Cardiovascular Therapeutics Conference in
Washington D.C., and the November 2006 annual meeting of the American
Heart Association in Chicago.

   "Publication in the JACC, a very prestigious peer-reviewed
journal, significantly increases the visibility of Dr. Sianos' results
to the entire cardiology community. We believe this will have a
favorable effect on the treatment choices made by the
interventionalists who treat these seriously ill patients," concluded
Dutcher.

   Additional On-Line Discussions of the Study to Highlight
Implications and Benefits

   On August 6, 2007, an article summarizing the study's findings was
posted at www.theheart.org, a website addressed to cardiologists,
referring physicians, and allied healthcare professionals, providing
information on caring for patients with disorders of the heart and
circulation. The article notes that "one-third of the patients
classified as having large thrombus burden receive thrombectomy," and
quotes Dr. Sianos as saying the patients "did better clinically and
experienced lower stent-thrombosis rates. This was a completely
unexpected finding and it's encouraging."

   Also, www.cardiosource.com, an online cardiovascular information
and educational resource produced by the American College of
Cardiology Foundation, plans to soon post an audio interview with Dr.
Sianos, who will discuss his findings as published in the JACC and
their impact on heart attack patient treatment. Cardiosource enables
cardiovascular medical professionals to easily stay up-to-date with
the most relevant research findings and best practices, with analysis
and commentary by experts in the field to help put new findings in
perspective for immediate application to clinical practice.

   About Possis Medical, Inc.

   Possis Medical, Inc., develops, manufactures and markets
pioneering medical devices for the large and growing cardiovascular
and vascular treatment markets. The company's AngioJet System is the
world's leading mechanical thrombectomy system with FDA approval to
remove large and small thrombus from coronary arteries, coronary
bypass grafts, peripheral arteries and veins, A-V grafts and native
fistulas.

   Certain statements in this press release constitute
"forward-looking statements" within the meaning of Federal Securities
Laws. These statements relate to the potential impact of clinical
science on usage of the Possis AngioJet System. These statements are
based on our current expectations and assumptions, and entail various
risks and uncertainties that could cause actual results to differ
materially from those expressed in such forward-looking statements. A
discussion of these and other factors that could impact the Company's
future results are set forth in the cautionary statements included in
the company's Form 10-K for the year ended July 31, 2006, filed with
the Securities and Exchange Commission.


    CONTACT: Possis Medical, Inc.
             Jules L. Fisher
             Vice President, Finance and Chief Financial Officer
             763-450-8011
             Jules.Fisher@possis.com